GleamWall
中文EN

CNSP CNS Pharmaceuticals, Inc.

Pharmaceutical Preparations · Nasdaq · SEC CIK 1729427 · Fiscal year ends 12/31

Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY—
TTM net income YoY-22.3%
TTM EPS YoY-102.7%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—

Margins

Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—

Returns

ROE-124.8%
ROA-106.8%
ROIC (approx.)—
Asset turnover—

Leverage & solvency

Liabilities / assets13.1%
Debt / equity0.00x
Current ratio7.65x
Interest coverage-1,031.22x

Cash quality & payout

Operating cash flow / net income0.88x
Accruals ratio-13.1%
Payout ratio—
Capex / revenue—

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item FY20252025-12-31FY20242024-12-31
Income statement
Revenue——
R&D expense$9.77M$9.29M
SG&A expense$6.21M$5.61M
Operating income-$15.99M-$14.90M
Interest expense$15,230$16,120
Income tax$0$0
Net income-$15.85M-$14.86M
EBITDA-$15.98M-$14.90M
EPS (basic)-35.75-466.89
EPS (diluted)-35.75-466.89
Weighted avg. shares (diluted)443,36931,823
Balance sheet
Cash & equivalents$7.20M$6.46M
Current assets$8.10M$8.66M
PP&E, net$18,000$6,005
Total assets$8.62M$8.70M
Current liabilities$4.10M$2.52M
Total liabilities$4.10M$2.52M
Shareholders' equity$4.52M$6.18M
Shares outstanding632,516117,796
Cash flow statement
Operating cash flow-$13.81M-$17.11M
Capital expenditure$18,175$4,188
Free cash flow-$13.83M-$17.12M
Investing cash flow-$18,175-$4,188
Financing cash flow$14.57M$23.03M
Depreciation & amortization$3,918$3,306
Stock-based compensation$187,728$838,957

Free plan shows the latest 2 periods; Pro shows all 8 🔒

· This company does not report gross profit in XBRL.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.